Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rocapuldencel-T - Argos Therapeutics

Drug Profile

Rocapuldencel-T - Argos Therapeutics

Alternative Names: AGS-003; CMN-001

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Argos Therapeutics Inc
  • Developer Argos Therapeutics Inc; CoImmune; GU Research Network; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 02 Oct 2023 CoImmune terminates phase-II trial in Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (Intradermal) (NCT04203901)
  • 28 Feb 2019 CoImmune acquires CMN 001 from Argos Therapeutics (CoImmune website - July 2023)
  • 01 Jun 2018 Updated Interim efficacy analysis from a phase III ADAPT trial in Reneal cell carcinoma (Metastatic) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO- 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top